tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Neumora Therapeutics downgraded to Underweight from Neutral at JPMorgan

JPMorgan downgraded Neumora Therapeutics (NMRA) to Underweight from Neutral without a price target The company’s Phase 3 KOASTAL-1 trial evaluating navacaprant as a monotherapy treatment in major depressive disorder failed to hit its primary endpoint or key secondary endpoint earlier this year, the analyst tells investors in a research note. The firm believes Neumora shares will continue to underperform peers into the Phase 3 KOASTAL-2 and KOASTAL-3 trial readouts.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1